A Look Inside the Podiatry Fellowship with Dr. Brennen O'Dell

Congratulations to Brennen O'Dell, DPM, upcoming graduate of the Michigan Medicine Podiatry Fellowship Training Program!

Dr. Brennen O’Dell completed his residency at Intermountain Medical Center, received his Doctor of Podiatric Medicine (DPM) degree from Des Moines University College of Podiatric Medicine and Surgery, and then joined the Michigan Medicine Podiatry Fellowship Training Program in July 2021.

Dr. O’Dell is an outstanding and valued member of our team. In addition to seeing patients in the podiatry clinic and at the hospital for inpatient care, he's actively involved in our program’s research efforts, including a program improvement project that impacted surgical care by improving the program's surgical preference cards. Dr. O'Dell has also published four articles, along with an additional publication that's been submitted, while in the program.

Dr. O’Dell was a third place award winning presenter at the 2023 Michigan Podiatric Medical Association (MPMA) Great Lakes Conference and has given over 22 presentations at various internal and external conferences, including the Symposium on Advanced Wound Care, the American Podiatric Medical Association Annual Conference, and the Division of Metabolism, Endocrinology & Diabetes 3rd Annual Diabetic Foot Conference.

Dr. O’Dell will stay on at Michigan Medicine as a new faculty member beginning July 1. Below he shares his experience in the program and what he's learned.

What is the most important thing you’ve learned while doing your fellowship?

The most important thing that I have learned is managing multiple projects at once. During fellowship, there are many demands and projects that are constantly happening, such as inpatient management, research projects, presentations, and clinic responsibilities. This fellowship helps to develop each of these areas, while also teaching how to better manage time to ensure that each is given the appropriate time and attention that is needed.

What aspects of the fellowship do you enjoy the most?

There are several areas that I enjoyed, but I think the most gratifying is seeing the progression of an idea turn into a research project and into publications. It is a long process, but one that you feel very proud of by the end.

How do you think the fellowship has prepared you for the future?

Fellowship has really helped me to identify how I wish to practice podiatric medicine and surgery. I enjoy the academic setting and working with a multidisciplinary team. I believe it helps to provide the best patient care. I have also learned the importance of research and education and striving to continue contributing scholarly work.

What research projects did you work on, what were the goals, and why were you interested in the topics?

My main research project was to evaluate the effect of statin therapy on the healing of diabetic foot ulcerations. Unfortunately, we did not find that it was helpful in the healing of diabetic foot ulcerations, but it was important to contribute this knowledge. I think strong research on healing diabetic foot ulcerations is always needed, so this was an area that I wanted to try and contribute.

How do you spend your day when you’re in the clinic?

We have admin time on our clinic days and I spend that hour of admin time chart checking our inpatient list so that I am current on each treatment plan. Then, we have clinic and usually see five-six patients during the morning and staff it with our assigned attending. Following clinic, we go to the hospital for any inpatient care that needs to be done (rounding, orders, surgeries, etc.).

What accomplishment are you most proud of?

I am proud of reaching the end of my formal training period. Undergraduate studies, podiatry school, residency, and fellowship is a long educational road, and I am proud to have completed each of these. I am most proud of my wife and two young boys that have been part of the entire journey with me.

What is your favorite part of your job?

My favorite part of the job is clearing diabetic foot infections and healing wounds. Whether these are healed through surgery or with continued wound care, I am proud to get them on the road to returning to their daily lives.

In This Story

brennen Odell

Brennen L O'Dell, DPM

Clinical Assistant Professor

Featured News & Stories

Dr. Njira Lugogo
Department News

Dr. Njira Lugogo Named Healthcare Hero by Crain's Detroit Business

Dr. Njira Lugogo, clinical professor of pulmonary and critical care medicine, was named one of Crain Detroit Business's 2026 Healthcare Heroes.
woman itching skin orange blue button down
Health Lab

A first-of-its-kind treatment for mastocytosis

A new drug called Avapritinib achieved longterm safety approval for indolent systemic mastocytosis.
Hello and welcome message
Department News

Biological Chemistry welcomes new MS and PhD students

New graduate students join the Department of Biological Chemistry at U-M Medical School.
kid at table not wanting to eat breakfast with parent blurred in background white coloring milk on table
Health Lab

Many parents face challenges getting kids to eat a healthy breakfast before school

Three-quarters of parents report at least one barrier to their child starting the day with a healthy meal on a typical school day, according to the University of Michigan Health C.S. Mott Children’s Hospital National Poll on Children’s Health.
Bill and Sally Martin stand affectionately with their arms around each other. They appear to be in a high open tower above a city.
Philanthropy News

A Gift to Benefit All: Bill and Sally Martin’s Visionary Support for Sports Medicine

With strong ties to U-M athletics, Bill and Sally Martin have made a gift to kickstart fundraising for the Nathan and Catherine Forbes Sports Medicine Institute at the University of Michigan.
Microscope images of prostate cancer cells
Health Lab

New drug combination may help treat advanced prostate cancer

University of Michigan researchers found that combining BET bromodomain and DNMT inhibitors may slow the growth of treatment-resistant prostate cancer by targeting transdifferentiated tumors.